DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
2 Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space Visit Post
3 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
4 Venous Thromboembolism Market Growth Quadrant to Balloon Up Visit Post
5 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
6 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
7 Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market Visit Post
8 MedTech Wrap Up Visit Post
9 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
10 Bayer's CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle Visit Post
11 Charting out the COVID-19 Vaccine Landscape Visit Post
12 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
13 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
14 Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance Visit Post
15 Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M Visit Post
16 E-Pharmacies: A Disruptive Innovation and the Future of Pharma Sector Visit Post
17 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
18 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
19 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
20 Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck Visit Post
21 Applications of AI in Healthcare: COVID-19 and Beyond Visit Post
22 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
23 The Mesh of the Generics and the Potential of Emerging Therapies in the Smoking Cessation Market Visit Post
24 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
25 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
26 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
27 Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End Visit Post
28 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
29 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Visit Post
30 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
31 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
32 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
33 8 Of The Most Common Foods Allergies - Do You Have One? Visit Post
34 FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel Visit Post
35 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
36 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
37 Bioterrorism: A Threat To The Healthcare And Global Peace Visit Post
38 Novartis' COVID-19 deal; Shattered hopes for Remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar Visit Post
39 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
40 FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M Visit Post
41 Pfizer's COVID-19 Vaccine; Calliditas' NefIgArd trial; ViiV's HIV Prevention Treatment; Biogen’s Aducanumab Rejection Visit Post
42 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
43 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
44 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
45 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
46 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
47 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
48 Inovio's COVID vaccine trial On-hold; Appeal to Pfizer; XtalPi's massive raise; GSK Nucala's HES approval; J&J's COVID vaccine Visit Post
49 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
50 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
51 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
52 Cycle Pharmaceuticals' USD 25M Debt Financing; Bayer’s Phase IV REPLACE Trial; Verona's Pilot Study with pMDI Ensifentrine in COVID Patients Visit Post
53 Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK's COVID-19 monoclonal antibody therapy; AstraZeneca's Farxiga scores goal in Phase III CDK trial Visit Post
54 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
55 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
56 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
57 Infectious Diseases That Possess Significant Challenge To Humans Health Visit Post
58 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
59 In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player Visit Post
60 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
61 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
62 The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For Visit Post
63 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
64 Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern Visit Post
65 The Increasing Global Burden of Cytomegalovirus Seroprevalence Visit Post
66 Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114's Phase III result Visit Post
67 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
68 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
69 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
70 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
71 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
72 Keeping a track on COVID-19 through Wearable Technology Visit Post
73 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
74 Security Breach: A Growing Concern For The Healthcare Industry Visit Post
75 Will there be a second wave of coronavirus? Visit Post
76 Telehealth: Opportunities and Hurdles in Virtual Healthcare Market Visit Post
77 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
78 Potential Diagnostic solutions that may significantly contribute to COVID-19 detection Visit Post
79 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
80 Novel coronavirus crumbles down as soon as it lands on copper Visit Post
81 Supply shortage: Why ventilators are in demand amid the Coronavirus crisis Visit Post
82 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
83 Is Hydroxychloroquine the answer to all the COVID-19 questions? Visit Post
84 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
85 COVID-19 crisis can prove to be a catalyst for Artificial Intelligence in Healthcare Visit Post
86 World Health Day Visit Post
87 Telemedicine: Can it be the future of healthcare? Visit Post
88 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
89 Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared? Visit Post
90 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
91 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
92 Should you wear contact lenses amid coronavirus outbreak? Visit Post
93 Questions and Answers on the Novel Coronavirus Disease (COVID-19) Visit Post
94 Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline Visit Post
95 Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development Visit Post
96 Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver Visit Post
97 Wuhan Coronavirus: A global emergency Visit Post
98 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
99 Marijuana as a treatment approach Visit Post
100 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
101 National Influenza Vaccination Week Visit Post
102 World AIDS Day- 2019 Visit Post
103 Antimicrobial resistance crisis: A global need for antibiotic awareness Visit Post
104 Onychomycosis therapeutics market: Impact of new topical anti-fungal drugs Visit Post
105 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
106 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
107 HIV Treatment Landscape and A New Approach Visit Post
108 Frightening Surge in HIV-drug Resistance: The Biggest Challenge Ahead Visit Post
109 Global Hepatitis B Market Size Visit Post
110 World Hepatitis Day Visit Post
111 Is it Okay to take Antibiotics without a prescription? Visit Post
112 Is Parainfluenza virus contagious? Visit Post
113 Beware! Season of Lyme has come Visit Post
114 Acute Bacterial Skin and Skin Structure Infections Emerging Therapies Visit Post
115 ABSSSI Current Therapeutic Market Visit Post
116 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
117 World Malaria Day Visit Post
118 Notizia Visit Post
119 The Business Cocktail Visit Post
120 World Tuberculosis Day Visit Post
121 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
122 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
123 CRISPR proves to be a blessing for LASSA fever Visit Post
124 Notizia Visit Post
125 WORLD AIDS DAY - 2018 Visit Post
126 Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships Visit Post
127 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
128 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
129 Notizia Visit Post
130 Notizia Visit Post
131 SNIPPET Visit Post
132 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
133 The Business Cocktail(Therapeutics) Visit Post
134 Parkinson's and tuberculosis shares a common protein that could provide better drugs for both Visit Post
135 Potential cure for Common cold Visit Post
136 Notizia Visit Post
137 Gilead Sciences  launched a highly effective hepatitis C drug Sovaldi Visit Post
138 Business Cocktail Visit Post
139 Notizia Visit Post
140 Notizia Visit Post
141 Notizia Visit Post
142 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
143 Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025 Visit Post
144 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
145 Business Cocktail Visit Post
146 Antibiotic Resistance: The Big Challenge of Healthcare Industry Visit Post
147 Hepatitis C drugs re-energize global fight over patents Visit Post
148 Vulvovaginal Candidiasis Visit Post
149 Cytomegalovirus infection Market Visit Post
150 Science Events of the Year Visit Post
151 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
152 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
153 Merck’s Antibody for Clostridium Difficile Visit Post
154 Biosimilar Market in India Visit Post
155 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
156 Dengvaxia: Boon for Dengue Visit Post
157 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
158 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
159 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
160 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
161 Futuristic Customizable RNA Vaccine Visit Post
162 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
163 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
164 DelveInsight’s Infectious disorders based Gene Therapy Reports Visit Post
165 Infectious Disease and Vaccines Pipeline Reports Visit Post
166 Ebola Virus Drugs Approved or Still in Pipeline. What’s the mystery? Visit Post